Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 5.3% – Here’s Why

by · The Cerbat Gem

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report)’s share price fell 5.3% during trading on Friday . The stock traded as low as $15.23 and last traded at $15.4590. 157,300 shares changed hands during trading, a decline of 83% from the average session volume of 946,983 shares. The stock had previously closed at $16.33.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on EYPT shares. Royal Bank Of Canada lifted their price objective on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th. TD Cowen raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th. Mizuho set a $28.00 price target on Eyepoint Pharmaceuticals in a report on Monday, October 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $29.25.

View Our Latest Stock Report on EYPT

Eyepoint Pharmaceuticals Trading Down 7.5%

The business has a 50-day simple moving average of $16.14 and a 200 day simple moving average of $13.34. The stock has a market cap of $1.25 billion, a P/E ratio of -5.04 and a beta of 1.63.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. The company had revenue of $0.97 million during the quarter, compared to the consensus estimate of $3.33 million. As a group, equities analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Insider Activity at Eyepoint Pharmaceuticals

In other news, insider Ramiro Ribeiro sold 42,544 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Aberdeen Group plc boosted its holdings in shares of Eyepoint Pharmaceuticals by 101.6% in the 4th quarter. Aberdeen Group plc now owns 1,605,984 shares of the company’s stock worth $29,341,000 after purchasing an additional 809,182 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Eyepoint Pharmaceuticals by 31.2% in the fourth quarter. Nisa Investment Advisors LLC now owns 42,655 shares of the company’s stock worth $779,000 after purchasing an additional 10,155 shares during the last quarter. Cyndeo Wealth Partners LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 3.4% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 22,990 shares of the company’s stock valued at $420,000 after acquiring an additional 760 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new stake in shares of Eyepoint Pharmaceuticals during the third quarter valued at approximately $28,556,000. Finally, Millennium Management LLC lifted its position in Eyepoint Pharmaceuticals by 1,166.2% during the third quarter. Millennium Management LLC now owns 483,054 shares of the company’s stock valued at $6,879,000 after buying an additional 444,905 shares during the period. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals Company Profile

(Get Free Report)

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

Further Reading